With COVID Crash In Sight, Moderna’s Post-Pandemic Future Starts To Take Shape
Executive Summary
The company reported a fourth quarter decline in SARS-CoV-2 vaccine sales and guided for sales of $5bn in 2023. It is looking ahead to filing for approval of its RSV vaccine.
You may also be interested in...
Can Courts And States Override FDA’s Drug Regulatory Authority?
Dueling suits seek to force US FDA to withdraw approval of mifepristone or prevent it from doing so while legislation introduced in Idaho would outlaw the use of mRNA technology. Lawyers say these are worrisome challenges to the agency's scientific judgement.
Gilead CAR-T Joins Billion-Dollar Club As Biktarvy Sales Cross $10bn Mark
Yescarta surged ahead of competitors Kymriah and Breyanzi, helping Gilead’s oncology sales exceed $2bn, while the company reported the strongest sales in its HIV-dominated core business since 2015.
Merck & Co. Remains 'Very Confident' In TIGIT
Despite initial underwhelming competitive data on the cancer target, Merck said it is expanding its investment behind its anti-TIGIT drug vibostolimab. Roche updated investors on its program too.